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Abstract
Replicative senescence forms a major barrier to tumor progression. Cancer cells bypass this by using one of the
two known telomere maintenance mechanisms: telomerase or the recombination-based alternative lengthening of
telomeres (ALT) mechanism. The molecular details of ALT are currently poorly understood. We have previously
shown that telomerase is actively repressed through complex networks of kinase, gene expression, and chromatin
regulation. In this study, we aimed to gain further understanding of the role of kinases in the regulation of telome-
rase expression in ALT cells. Using a whole human kinome small interfering RNA (siRNA) screen, we highlighted
106 kinases whose expression is linked to human telomerase reverse transcriptase (hTERT) promoter activity. Network
modeling of transcriptional regulation implicated c-Myc as a key regulator of the 106 kinase hits. Given our previous
observations of lower c-Myc activity in ALT cells, we further explored its potential to regulate telomerase expression
in ALT. We found increased c-Myc binding at the hTERT promoter in telomerase-positive compared with ALT cells,
although no expression differences in c-Myc, Mad, or Max were observed between ALT and telomerase-positive cells
that could explain decreased c-Myc activity in ALT. Instead, we found increased expression of the c-Myc competitive
inhibitor TCEAL7 in ALT cells and tumors and that alteration of TCEAL7 expression levels in ALT and telomerase-positive
cells affects hTERT expression. Lower c-Myc activity in ALT may therefore be obtained through TCEAL7 regulation.
Thus, TCEAL7 may present an interesting novel target for cancer therapy, which warrants further investigation.
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Introduction
The induction of the permanent cell cycle arrest known as cellular
senescence is a major barrier to tumor progression [1–3]. Most human
cancers bypass telomere-dependent replicative senescence through tran-
scriptional up-regulation of the telomerase subunits human telomerase
RNA (hTR) and human telomerase reverse transcriptase (hTERT)
[4,5]. However, up to 77% of some mesenchymal tumor types [6,7]
use the intertelomeric and intratelomeric recombination-based mecha-
nism known as alternative lengthening of telomeres (ALT) [8]. Themo-
lecular details behind the decision to activate ALTor telomerase during
the process of immortalization are still poorly understood. ALT has prog-
nostic significance in a number of tumor types [9–13], and because ALT
tumors do not express significant levels of telomerase, telomerase-centered
therapeutics are unlikely to be of benefit to ALT tumor treatment. An
improved understanding of regulatory processes underlying the ALT
phenotype may yield potential targets for future intervention therapy.
Our previous studies have shown the existence of a complex net-
work of interactions through kinases [14], gene expression alterations
[15], and chromatin modification [16] that regulate telomerase expres-
sion in ALT and telomerase-positive cells. Network modeling of ex-
pression data also highlighted a potentially decreased level of c-Myc
activity in ALT cells, which we confirmed using an ELISA assay for
c-Myc DNA binding [15]. The Myc gene family is frequently over-
expressed in cancer [17] and is involved in the regulation of the cell
cycle, angiogenesis, and cell adhesion during neoplasia [18]. c-Myc
overexpression has been seen to be essential for an effective senescence
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bypass in melanoma and has proved an interesting target for senes-
cence induction therapy [19–21]. Furthermore, the expression of the
catalytic subunit of telomerase, hTERT, is activated by c-Myc [22].
Given the strict regulatory networks surrounding telomerase and the
decreased c-Myc activity in ALT cells, we have previously suggested
that c-Myc may be an important factor in the decision between the
use of ALT or telomerase during immortalization. Because we have
previously observed no significant difference in expression of c-Myc
between ALT and telomerase-positive cells, the regulatory mechanisms
behind the lower c-Myc activity in ALT remain to be elucidated.
In this study, we aimed to gain a further understanding of the role of
kinases in the complex regulatory network surrounding hTERT expres-
sion in ALT cells. Through the use of a small interfering RNA (siRNA)
kinase screen, we elucidated 106 kinases with the ability to affect hTERT
promoter activity by at least two-fold. Investigation of transcriptional
regulators of the kinase hits revealed c-Myc to be a critical regulator of
these kinases. In addition, through further investigation of c-Myc regula-
tion, we show that alterations in expression of the c-Myc competitive
inhibitor TCEAL7 may be one mechanism by which c-Myc activity
and hTERTexpression are differentially regulated in ALT cells.
Materials and Methods
Cell Culture
SKLU (lung adenocarcinoma), C33a (cervical carcinoma), and
SUSM1 (liver fibroblasts) were cultured in Dulbecco’s modified Eagle
medium (10% FBS and 2 mM L-glutamine) at 10% CO2. HT1080
(fibrosarcoma), KMST6 (lung fibroblasts), WI38-SV40 (SV40 immor-
talized lung fibroblasts), WI38 (normal lung fibroblasts), and IMR90
(normal lung fibroblasts) were cultured in minimum essential medium
(10% FBS and 2 mM L-glutamine) at 5% CO2. A2780 (ovarian car-
cinoma) and 5637 (bladder carcinoma) were cultured in RPMI 1640
(10% FBS and 2 mM L-glutamine) at 5% CO2. All culture media and
reagents were purchased from Invitrogen (Paisley, UK).
c-Myc Transcription Factor Binding Assays
Nuclear extracts were obtained from each cell line using the nu-
clear extract kit from Active Motif (Active Motif, Rixensart, Belgium)
as per the manufacturer’s instructions. c-Myc activity was measured
in duplicate samples for each cell line using TransAM transcription
factor binding ELISAs (Active Motif ) in triplicate as per the man-
ufacturer’s instructions. Briefly, nuclear extracts were incubated for
1 hour at room temperature with mild agitation in microwells coated
with consensus c-Myc oligonucleotide. After incubation, wells were
washed and probed for 1 hour with 1:1000 dilution of c-Myc antibody.
Antibody binding was detected using HRP-conjugated secondary and
the addition of developing and stop solutions. Optical density of wells
was measured at 450 nm, and a standard curve of recombinant c-Myc
protein was included in each assay along with blank negative control
and positive control wells containing Jurkat cell extract.
siRNA and Overexpression Plasmid Transfections
Whole kinome siRNA library screen (Applied Biosystems, Inc,
Foster City, CA) in SKLU cells was performed as previously pub-
lished [14]. In brief, 50 nM siRNA or noncoding siRNA control
(Applied Biosystems, Inc) were cotransfected with 250 ng of hTERT
reporter plasmid in 96-well plates (Thermo-Fisher Scientific, Rochester,
NY) using Lipofectamine 2000 (Invitrogen) according to the manu-
facturer’s instructions. Cell lysis was achieved using passive lysis buffer
(Promega, Madison, WI). Luciferase assay system (Promega) was
used to determine luciferase activities according to the manufacturer’s
instructions. TCEAL7 siRNA transfections were performed using
Dharmacon Smartpools (Thermo-Fisher Scientific) in 75-cm2 flasks.
TCEAL7 siRNA transfections for c-Myc activity were performed in
125-cm2 flasks. pCMV-XL4:TCEAL7 overexpression plasmid was
purchased from Origene Technologies, Inc (Rockville, MD), and all
transfections were performed in 75-cm2 flasks. All transfections were
performed in triplicate.
Bioinformatic Analysis
Fully MIAME-compliant gene expression microarray data were pre-
viously submitted to GEO under the accession numbers GSE14487
and GSE17118. Data were normalized to the 75th percentile using
Genespring GX (version 7.3; Agilent Technologies UK Ltd., South
Queensferry, UK), and c-Myc, Mad, and Max probe-normalized inten-
sities were exported to Excel (Microsoft Corporation, Redmond, WA)
for visualization. The interval plot of mesenchymal tumor data was
produced using Minitab (version 15; Minitab, Inc, State College, PA).
Transcriptional regulation networks were generated using transcriptional
regulation algorithms inMetaCore (Genego, St Joseph, MI; filters: posi-
tive and negative regulations, all mechanisms).
c-Myc Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) assays were performed as
per the manufacturer’s instructions (Millipore, Watford, UK) as pre-
viously published [14]. No antibody pull-downs were performed as
negative controls for each immunoprecipitation. Data are presented
as percentage of input after subtraction of any background detected
in the no antibody control.
RNA Extraction and Quantitative Polymerase Chain Reaction
RNA was extracted using the Nucleospin II RNA extraction kit
(Macherey-Nagel, Duren, Germany) according to the manufacturer’s
instructions. TCEAL7 and hTERT quantitative polymerase chain re-
action (qPCR) and hTERT promoter ChIP qPCR was performed
using the DyNAmo Hot star SYBR Green kit (Finnzymes, Espoo,
Finland) and Opticon 2 DNA Engine from MJ Research. Primer se-
quences were as follows:
TCEAL7f: GAAGGAAGAGCTGGTTGAT
TCEAL7r: GACCCCTTATCTCTTCCAA
hTERTf: CTGCTGCGCACGTGGGAAGC
hTERTr: GGACACCTGGCGGAAGGAG
CHIPTERTf: TCCCCTTCACGTCCGGCATT
CHIPTERTr: AGCGGAGAG AGGTCGAATCG
All qPCRs were normalized to S15 expression before taking fold of
control. S15 primers were as follows:
S15f: TCCGCAAGTTCACCTACC
S15r: CGGGCCGGCCATGCTTTACG
All qPCR experiments were performed in triplicate.
Telomerase Activity Assay
The TRAPeze XL kit was used for telomere repeat amplification
protocol (TRAP) assay according to the manufacturer’s instructions
(Millipore) as previously published [14].
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Statistical Analysis
Statistical analysis of ELISA, reverse transcription (RT)–PCR, and
TRAP assays were performed by unpaired t-test, using GraphPad Prism
software (GraphPad Software, San Diego, CA).
Results
siRNA Kinase Screen Highlights 106 hTERT
Regulatory Kinases
To probe kinase regulation of the ALT phenotype, we undertook an
siRNA kinase screen using an hTERT promoter luciferase reporter
construct in the ALT cell line SKLU. Three separate siRNA for 719
kinases and kinase-related genes were investigated. As in our previous
study [14], the cutoff we applied for hit assessment was a more-than
two-fold change in hTERT promoter activity in at least two of three
siRNAs. This resulted in 106 kinases that met the criteria (Figure 1
and Table W1). Examination of the regulatory effect of these hits
shows that 89 activate the hTERT reporter (promoter activity down-
regulated by siRNA) and 17 are inhibitors.
This interesting result indicates that SKLU cells retain many active
signaling components, which may be required for hTERT expression
in telomerase-positive cells. In the context of the ALT phenotype, it is
likely that their effects on telomerase are muted by additional regula-
tory systems including epigenetic changes at the hTERT promoter and
the altered gene expression networks we have previously observed. It
will be of interest to investigate the potential roles of the inhibitory
kinase hits identified here in these processes in future studies.
Transcriptional Regulation Networks of 106 hTERT
Regulatory Kinases Highlight the Importance of c-Myc
Given that we have previously shown that the ALT phenotype in-
volves an altered transcriptional profile, we used network modeling
to investigate which transcription factors might affect and/or be af-
fected by the kinases identified as hits. Application of the transcrip-
tional regulation network inference algorithm in MetaCore from
Genego returned several networks centered on individual high-degree
transcription factor neighbors of the hits, including a number with
known hTERT regulatory functions (Table 1). Union of the net-
works surrounding the hTERT transcriptional activators STAT3,
SP1, and c-Myc (Figure 2A) and repressors p53 and the Androgen
receptor (Figure 2B) highlights the interplay between multiple can-
didate pathways that might influence the expression of hTERT in
ALT cells.
We have previously shown that c-Myc activity is lower in ALT cells
compared with telomerase-positive cells resulting in changes in the
Figure 1. SiRNA kinase screen highlights 106 kinases with hTERT regulatory functions. Kinases with two siRNA that induce a two-fold or
more change in hTERT promoter activity in the same direction over promoter-less control plasmid. Each point indicates the average
change in promoter activity of two or more different siRNA for each kinase assayed in triplicate; error bars, SE of triplicate repeats.
Table 1. Transcriptional Regulation Analysis of 106 hTERT Regulating Kinases in MetaCore from
Genego Shows Known hTERT Regulating Transcription Factors and c-Myc as the Most Signifi-
cant Regulator.
No. Network % of Hits Regulated P
1 c-Myc 17 1.50e−48
2 HNF4-α 15 2.42e−40
3 p53 14 1.28e−37
4 SP1 13 6.67e−35
5 STAT3 11 1.73e−29
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expression of c-Myc downstream targets. Interestingly, c-Myc regu-
lates the largest percentage of kinase hits in this study (Table 1),
showing not only that c-Myc itself is involved with telomerase regu-
lation in ALT but also that its downstream kinases are regulators
themselves of telomerase expression. Given the increasing evidence
for the central role of c-Myc in this process, we further investigated
the factors potentially regulating c-Myc activity in ALT cells.
Telomerase-Positive Cells Have Increased Binding of c-Myc at
the hTERT Promoter but Show No Change in Binding
Partner Expression
The role of epigenetic changes in hTERT promoter silencing is well
established. However, the landscape of sequence-specific transcription
factors associated with the hTERT promoter in ALT remains unclear,
although it is predictable that many positively acting factors will be
excluded or present in profoundly altered complexes. To compare
the influence of c-Myc at the hTERT promoter between ALT and
telomerase-positive cells, we performed ChIP using a c-Myc antibody
and qPCR for the hTERT promoter in the resulting pull-down
(Figure 3A). Within the telomerase-positive cell lines, HT1080 and
C33a showed the highest levels of c-Myc immunoreactivity. A2780
cells had the lowest levels of c- Myc detected at the hTERT promoter;
however, these were two-, five-, and seven-fold greater than SUSM-1,
WI38-SV40, and KMST6, respectively (note the log scale). No signal
above background was detected in SKLU cells. This is consistent with
our previous findings of decreased c-Myc activity and inhibitory chro-
matin modifications at the hTERT promoter in ALT cells and might
reflect either decreased site occupancy or epitope masking in ALT cells.
Relative levels of Myc/Max versus Mad/Max binding have previ-
ously been observed to regulate the hTERT promoter chromatin en-
vironment, raising the interesting possibility that E-boxes might play
a role in establishment of epigenetic silencing of telomerase in ALT.
Using our gene expression microarray data on the ALT and telome-
rase cell lines, we investigated whether the difference in c-Myc bind-
ing at the hTERT promoter could be accounted for by expression
differences in Mad and Max. We observed no significant difference
in expression of c-Myc itself or Mad and Max between the ALT and
telomerase-positive cell lines (Figure 3B).
Given the lack of differences in expression of c-Myc, Max, or Mad
between ALTand telomerase cell lines that could explain the decrease
of c-Myc activity observed in ALT, we decided to investigate other
possible mechanisms for c-Myc regulation.
Differential Expression of c-Myc Inhibitor TCEAL7 in ALT
and Telomerase-Positive Cell Lines
The transcription elongation factor A (SII)-like protein TCEAL7
has recently been shown to inhibit c-Myc activity through the com-
petitive binding of E-boxes [23]. Such competitive inhibition would
allow regulation of c-Myc transcriptional activity without the need
for a down-regulation in expression. We examined TCEAL7 expres-
sion to assess whether it might regulate c-Myc activity in ALT and
telomerase-positive cells. Figure 4A shows RT-qPCR for TCEAL7
in the ALT and telomerase-positive cell lines. Three of the four
ALT cell lines have high levels of TCEAL7 expression, whereas the
telomerase-positive cells have little or no expression of this gene. Co-
immunoprecipitation experiments showed no direct interaction be-
tween TCEAL7 and c-Myc in any of the ALT or telomerase-positive
cell lines (data not shown), suggesting that TCEAL7 regulation of
c-Myc activity in ALT is through competitive inhibition.
Figure 2. Transcriptional regulation networks highlight synergistic regulation of hTERT regulatory kinases by known hTERT transcrip-
tional regulators. Merged networks of the five highest scoring transcriptional regulators of 106 siRNA kinase screen hits of known
hTERT transcriptional activators (A) and repressors (B). Green lines between objects indicate an activating interaction, whereas red lines
indicate an inhibitory reaction. Overlaid line colors (red, green, or blue) indicate transcriptional networks generated for each transcription
factor before network merge. Symbols on the lines indicate the following: TR = transcriptional regulation, +P = phosphorylation, B =
binding, and ? = unknown mechanism. Blue circles next to kinases indicate an hTERT activating kinase, and red circles indicate an
hTERT inhibiting kinase.
Figure 3. c-Myc shows increased binding at the hTERT promoter in
telomerase-positive cells, which cannot be explained by common
c-Myc binding partner expression patterns in ALT and telomerase-
positive cells. (A) ChIP analysis of the hTERT promoter was com-
pleted using an antibody against c-Myc performed in duplicate.
Each immunoprecipitate was quantified in triplicate by qPCR analy-
sis and related back to an input sample in each experiment to nor-
malize the data. Error bars, SE of duplicate experiments. (B) Gene
expressionmicroarray data for c-Myc,Mad, andMax in ALT cell lines
(SUSM1, KMST6, WI38-SV40, and SKLU) and telomerase-positive
cell lines (HT1080, C33a, 5637, and A2780). Results are representa-
tive of one probe for c-Myc and themean and SE of duplicate probes
for Mad and triplicate probes for Max. Data were previously submit-
ted to GEO under accession number GSE14487.
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ALT is predominantly found in tumors of mesenchymal origin
in vivo [6,7]; therefore, to investigate whether the increased expres-
sion of TCEAL7 is observed in ALT tumors, we used our gene
expression microarray data on three mesenchymal tumor types: lipo-
sarcomas, peritoneal mesotheliomas, and malignant peripheral nerve
sheath tumor [15]. Figure 4B shows that, in our mesenchymal tumor
cohort, ALT tumors express higher levels of TCEAL7 than telomerase-
positive tumors (t = 1.99, P = 0.053, df = 42). This suggests that
TCEAL7 could regulate c-Myc activity both in vitro and in vivo.
TCEAL7 Affects c-Myc Activity, hTERT Expression, and
Telomerase Activity
To investigate the effects of altering TCEAL7 in ALT cells, we per-
formed siRNA knockdowns using a pool of three different siRNA.
Figure 5A shows that, in all four ALT cell lines, TCEAL7 expression
was reduced in comparison to nonspecific siRNA control. We there-
fore examined the effect of TCEAL7 knockdown on c-Myc activity
in ALT cells using transcription factor binding ELISAs. Figure 5B
shows that TCEAL7 knockdown caused strong induction of c-Myc
activity in WI-38 and SUSM1 cells, suggesting suppression of c-Myc
DNA binding activity in ALT cells which overexpress TCEAL7. In
contrast, c-Myc DNA binding activity was not significantly affected
in SKLU or KMST6 cells. As SKLU and KMST6 express less TCEAL7
than WI-38 and SUSM1, it is possible that other factors contribute
to low c-Myc activity these cells.
Because we have seen lower levels of c-Myc binding at the hTERT
promoter in ALT cells, we investigated whether TCEAL7 expression
knockdown and the resulting changes in c-Myc activity are sufficient
to alter the expression of hTERT in ALT cells using RT-qPCR analy-
sis of full-length hTERT (Figure 5B). TCEAL7 knockdown signifi-
cantly induced hTERT expression in SUSM1 cells, confirming that
TCEAL7 can play a role in the suppression of hTERT expression in
some ALT cells. Interestingly, hTERT expression was decreased in
SKLU and KMST6, also suggesting active E-box–dependent regula-
tion of telomerase, although c-Myc activity was relatively unaffected
in these cells. Therefore, additional mechanisms for c-Myc suppression
may also be present. One possibility is that TCEAL7 knockdown pref-
erentially relieves Mad rather than c-Myc targeting to E-boxes in these
cells resulting in further reduction of hTERT expression. In WI38-
SV40 cells, hTERT was not significantly affected as a result of
TCEAL7 knockdown.
Because telomerase-positive cells express little or no TCEAL7, we
investigated the effects of TCEAL7 overexpression in these cells. A
complementary DNA expression construct was transfected into the
four telomerase-positive cell lines, and the expression of TCEAL7 was
analyzed by RT-qPCR compared with an empty vector control. In all
four cell lines, TCEAL7 expression was significantly increased in com-
parison to empty vector control (Figure 6A). The effect of TCEAL7
overexpression on hTERT expression was then investigated using RT-
qPCR (Figure 6B). Expression of hTERT was decreased significantly
after TCEAL7 overexpression in A2780 and C33A cells. A decrease of
borderline significance was also observed in 5637 cells, although the
expression was unaffected in HT1080 cells. Because levels of c-Myc
binding at the hTERT promoter were highest in these cells (Figure 3),
more TCEAL7 may be required for successful competition.
Telomerase activity was assessed by TRAP assay after TCEAL7
overexpression, revealing significantly decreased levels in C33A and
HT1080 cells (Figure 6B). Interestingly, although 5637 cells showed
decreased levels of hTERT gene expression, telomerase activity in fact
increased with TCEAL7 overexpression. 5637 cells have relatively low
levels of hTERT transcription, and the down-regulation of hTERT
expressionmay trigger a regulatory feedback loop tomaintain basal telo-
merase activity through, for example, posttranscriptional mechanisms
such as alternative RNA splicing or hTERT phosphorylation. Regard-
less, taken together, the current results clearly indicate that TCEAL7 is a
novel regulator of hTERT expression and telomerase activity in both
ALT and telomerase-positive cell lines.
Discussion
ALT is predominantly found in tumors of mesenchymal origin [6,7]
and has prognostic significance in multiple tumor types [9–13]. Im-
proved understanding of the molecular mechanisms behind the deci-
sion to activate telomerase or ALT for immortalization may therefore
provide novel opportunities for intervention in these tumors. We have
previously shown that telomerase is strictly regulated at both the chro-
matin and gene expression levels in ALT cells [15,16]. Furthermore,
we have also shown that kinases play a role in regulation of telomerase
in telomerase-positive cells [14].
In this study, we initially probed the kinome for hTERT regulatory
kinases in ALT cells using an siRNA kinase hTERT luciferase reporter
Figure 4. TCEAL7 expression is increased in ALT cell lines and mes-
enchymal tumors. (A) S15normalizedqPCRofTCEAL7 in telomerase-
positive cell lines (HT1080, A2780, 5637, and C33A) andALT cell lines
(SKLU, KMST6, WI38-SV40, and SUSM1). Error bars, SE of triplicate
experiments. (B) Interval plot of gene expression microarray data for
TCEAL7 in three mesenchymal tumor types (liposarcoma, peritoneal
mesothelioma, and malignant peripheral nerve sheath tumor) sub-
mitted to GEO under accession number GSE17118. Crosshairs
showmean expression in telomerase-positive and ALT tumors; error
bars, 95% confidence intervals drawn using Minitab (version 15). t=
1.99, P = 0.053, df = 42.
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screen. This highlighted 106 kinases through which hTERT promoter
activity is regulated. A greater proportion of the hits observed were
activators, such that their knockdown resulted in decreased hTERT
promoter activity. Thus, our screening approach revealed that a sub-
stantial portion of the signaling machinery potentially required to sup-
port hTERT expression remains active in ALT cells. This observation
may have future therapeutic implications because it has been suggested
(although not experimentally observed) that the emergence of ALT
could represent a mechanism of resistance to telomerase directed ther-
apies. Furthermore, those hits identified as repressors of the hTERT
promoter might be worthy of investigation as candidate ALT targets
in their own right.
We previously adopted a network modeling approach to analyze a
unique ALT-specific gene expression signature. In this study, we used
our screening hits as a profile of active signaling pathways relevant to
telomerase regulation in ALT and applied network building algo-
rithms to investigate mechanisms of transcriptional control on these
pathways (Table 1). The algorithm returned several hTERT regula-
tory transcription factors as highly significant neighbors of the kinase
list, and we constructed network models around hTERT-activating
and -repressing factors highlighting candidate pathways that may
contribute to hTERT transcriptional repression in ALT. We have
therefore shown that the complex network of interactions by which
the expression of telomerase is regulated in ALT cells further extends
to kinase regulation, consistent with our findings in telomerase-
positive cells [14].
The most significant transcriptional regulator of the 106 kinase
hits was c-Myc, a known hTERT transcriptional activator [22]. Over-
expression of c-Myc is common in cancer, playing a regulatory role in
the cell cycle [19], angiogenesis, and cell migration [18,24]. c-Myc
Figure 5. Knockdown of TCEAL7 expression leads to increased c-Myc activity and increased hTERT expression in some ALT cells.
TCEAL7 knockdown using a pool of three independent TCEAL7 siRNA (Dharmacon) or noncoding siRNA control. Transfections were
performed in duplicate, and two independent experiments were analyzed. (A) qPCR of TCEAL7 expression normalized to S15 expression
before taking fold of control transfections. Error bars derived from two independent experiments with PCR done in triplicate. (B) hTERT
expression was normalized to S15 expression before taking fold of control transfections. Error bars derived from two independent ex-
periments with PCR done in triplicate. c-Myc activity was measured using transcription factor ELISA assays (Active Motif) performed in
duplicate. Recombinant c-Myc (Active Motif) was used to create a standard curve for relative quantification. Results represent mean and
SE of replicates derived from two independent transfections. P values were calculated using GraphPad Prism.
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therefore presents an attractive target for anticancer therapy. A recent
study found that the potent anticancer drug butein causes a decrease
in telomerase expression and inhibits cell proliferation through the
suppression of c-Myc expression [25]. Furthermore, recent evidence
that chromatin remodeling is required before c-Myc can access the
hTERT promoter for activation [26] is consistent with our previous
data showing that chromatin modification also plays a role in the lack
of hTERTexpression in ALT cell lines [16]. We have previously shown
that c-Myc activity is significantly decreased in ALT cells compared
with telomerase-positive cells [15], suggesting that c-Myc may have
a role the decision between the two telomere maintenance mechanisms
through telomerase regulation. To investigate this further, we used ChIP
to assess the relative levels of c-Myc binding at the hTERT promoter
in ALT and telomerase-positive cell lines. We found that telomerase-
positive cells had more c-Myc present at the hTERT promoter when
compared with ALT cells. c-Myc binds DNA at E-box sequences as a
dimer with binding partner Max to activate target genes [27]. In turn,
the activities of Max are antagonized by dimerization with Mad, and
the resulting binding of Mad/Max to E-boxes within promoter regions
leads to gene repression [28]. Furthermore, Mad has been found to di-
merize with and recruit the histone demethylase RBP2 to E-boxes in
the hTERT promoter and repress transcription through chromatin
remodeling [29]. The expression levels of Mad and Max in ALT and
telomerase-positive cells, therefore, may have an influence on the activ-
ity of c-Myc and telomerase expression. However, investigation of the
expression patterns using our gene expression microarray data showed
no significant difference in the expression of c-Myc, Mad, or Max be-
tween ALT and telomerase-positive cell lines.
Figure 6. Overexpression of TCEAL7 expression leads to decreased hTERT expression and telomerase activity in telomerase-positive
cells. TCEAL7 complementary DNA overexpression plasmid (Origene) or empty vector control plasmid was transfected into telomerase-
positive cells in duplicate, and two independent experiments were analyzed. (A) qPCR of TCEAL7 expression normalized to S15 expres-
sion before taking fold of control transfections. Error bars derived from two independent experiments with PCR done in triplicate. (B)
hTERT expression was normalized to S15 expression before taking fold of control transfections. Error bars derived from two indepen-
dent experiments with PCR done in triplicate. Telomerase activity was measured using TRAP assay. Error bars derived from duplicate
assays for two independent transfections. P values were calculated using GraphPad Prism.
412 Telomerase Regulation by c-Myc Through TCEAL7 Lafferty-Whyte et al. Neoplasia Vol. 12, No. 5, 2010
The lack of binding partner interactions able to account for the
decrease in c-Myc activity suggests a further layer of regulation of
c-Myc activity in these cells. To this end, we investigated the poten-
tial for TCEAL7 regulation of c-Myc activity in ALT and telomerase-
positive cells. TCEAL7 is a member of the transcription elongation
factor A (SII)-like gene family and is relatively poorly studied. The
expression of TCEAL7 is epigenetically silenced in epithelial ovarian
cancer, and forced expression of TCEAL7 in ovarian tumor cell lines
induced apoptosis [30]. Furthermore, TCEAL7 has been observed to
have decreased expression in a variety of human tumors [23], and re-
cently, polymorphisms in the gene have been associated with a reduced
risk of invasive serous ovarian cancers [31]. The role of TCEAL7 in
cancer risk may be due to its function as a regulator of cyclin D1 ex-
pression and c-Myc activity [23]. TCEAL7 binds to E-boxes of gene
promoters and thereby competitively inhibits gene activation by Myc-
Max complexes. Such competitive inhibition would effectively de-
crease c-Myc activity without the need for decreased c-Myc expression,
which would be consistent with our findings. RT-qPCR showed that
ALT cell lines, in general, express a high level of TCEAL7, whereas
telomerase-positive cell lines express little or no TCEAL7. Because
ALT is predominantly seen in mesenchymally derived tumors [6,7],
we also investigated TCEAL7 expression in our gene expression micro-
array data for three mesenchymal tumor types: liposarcomas, perito-
neal mesotheliomas, and malignant peripheral nerve sheath tumors.
We found that TCEAL7 expression is increased in ALT tumors com-
pared with telomerase-positive tumors (P = .053), suggesting that
TCEAL7 overexpression may be a c-Myc regulatory mechanism both
in vitro and in vivo.
To investigate the effect of perturbing TCEAL7 regulation in ALT
cells, we performed siRNA knockdown of TCEAL7 with a pool of
three separate siRNA oligonucleotides. TCEAL7 expression was suc-
cessfully knocked down in all four ALT cell lines and was associated
with significantly increased c-Myc activity in the two ALT cell lines
expressing high levels of TCEAL7, WI38-SV40, and SUSM1, sug-
gesting that TCEAL7 represents a potential c-Myc regulatory factor in
these cells. Furthermore, examination of hTERT expression in these
cell lines showed that the resulting c-Myc activity increase was suffi-
cient to create an increase in hTERT expression in these cells, which
reached significance in SUSM1.
The telomerase regulatory role of TCEAL7 was further investigated
in telomerase-positive cells. These cells expressed little or no endogenous
TCEAL7, however, overexpression resulted in a decrease in hTERT
expression in all four cell lines tested, which reached significance in
A2780 and C33A. We also found that in three of the telomerase-
positive cell lines, TCEAL7 overexpression induced a decrease in telo-
merase activity. This decrease reached statistical significance in two of
these cell lines. Consistent with the decreased expression of TCEAL7
in a wide variety of human tumors [23], these data combined suggest
that TCEAL7 expression in ALT and telomerase-positive cells is a po-
tentially important telomerase regulatory factor. The precise mechanism
by which TCEAL7 affects telomerase expression remains to be investi-
gated, although our ELISA results support inhibition of c-Myc DNA
binding in at least some cases, and we ruled out direct protein-protein
interactions by coimmunoprecipitation. Nevertheless, because most
transcription factors including c-Myc regulate gene expression through
complex mechanisms such as recruitment of chromatin remodeling
activities, it is likely that direct competition with c-Myc is only part
of the mechanism of action of TCEAL7; therefore, this warrants further
investigation in future studies.
In this study, we have highlighted 106 kinases with the ability to
regulate hTERTexpression in ALT cells. Furthermore, we have shown
that these kinases are regulated by known hTERTregulatory transcrip-
tion factors and, in particular, the transcription factor c-Myc. Given
that we have previously shown multiple gene expression changes in
c-Myc downstream targets and decreased c-Myc activity in ALT cells
[15], this study adds further weight to the importance of c-Myc in the
regulation of telomere maintenance mechanisms. In addition, we also
highlight competitive inhibition by TCEAL7 as a potential mechanism
by which c-Myc activity could be regulated in ALT cells with the abil-
ity to regulate hTERT expression in both ALT and telomerase-positive
cells. TCEAL7, therefore, presents an interesting novel therapeutic tar-
get. Further investigation of other regulatory targets of TCEAL7 may
improve understanding of the complex network of interactions in-
volved in the decision between telomere maintenance mechanisms
in carcinogenesis and present us with novel targets for intervention.
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Table W1. 106 hTERT Regulatory Kinase Hits from siRNA Kinase Screen.
Gene Name Average Fold Change of Hits SE
PIK3CD −7.626141 4.800253674
SYK −5.098573165 1.083809385
ERK8 −4.966383263 2.678485952
STK17A −4.584266024 0.347077659
EIF2AK3 −4.230699554 2.144300446
TESK1 −4.149368473 0.506389685
NME1 −4.116650177 1.56100046
STK3 −3.982190426 0.01160853
SGK2 −3.950789063 0.063974717
NEK2 −3.928606065 0.78728662
TEK −3.884075779 1.678196948
STK38L −3.883749892 0.881437024
T3JAM −3.870180587 1.219184054
TESK2 −3.868875476 0.590672629
GALK1 −3.854285413 0.204429505
STK22D −3.845985373 1.039685819
TRIB1 −3.806223057 0.347887277
TPK1 −3.628760965 0.396567982
STK10 −3.610932197 0.696506422
EEF2K −3.575328284 0.700765347
PRKWNK1 −3.568349593 1.145195615
PTK7 −3.564542557 0.915087073
STK32C −3.537720617 0.334747738
SGK −3.465247226 0.470530061
STK17B −3.457397979 0.167305813
MAPK3 −3.438331247 0.711668753
STK35 −3.429581105 0.062713415
TXNDC3 −3.374039754 0.42155578
SNRK −3.371617381 0.889176491
LOC390975 −3.365778539 0.117768589
TYK2 −3.342392656 0.36066751
STK11 −3.341422966 1.296867399
TTBK1 −3.33363146 0.580568101
STK22C −3.308104675 0.246671841
STK32A −3.19119096 0.710913631
SCGB2A1 −3.185512352 0.509234025
MKNK1 −3.16371589 0.187729048
STK24 −3.138801636 0.834250312
TAO1 −3.099429141 0.197176463
STK19 −3.046636846 0.005632869
DKFZp434B1231 −2.995779298 0.089117512
MAPK9 −2.979049408 0.69262267
SBK1 −2.974159689 0.649668727
PKMYT1 −2.970587472 0.581667753
SH3BP4 −2.889949215 0.372157411
MAPK8 −2.885391767 0.750862253
STK4 −2.8681816 0.166788638
COASY −2.830842483 0.477907517
SSTK −2.805823816 0.600913378
SIK2 −2.797723262 0.201541444
NEK9 −2.758967842 0.462898255
NEK8 −2.718078038 0.022309266
CDK6 −2.71642014 0.470176971
NEK7 −2.712912469 0.480187889
SPHK2 −2.666674382 0.047453491
PIP5K2C −2.664730487 0.583760458
CRIM1 −2.660157938 0.599694279
PGK2 −2.660078427 0.286089456
DGUOK −2.647652808 0.351214261
PRPSAP1 −2.63299534 0.445731933
CAMK1 −2.617912948 0.06272289
PRKCN −2.605991541 0.080080794
TXNDC6 −2.604711578 0.348232438
STK6 −2.586017026 0.583890063
PRKWNK2 −2.495208562 0.299481079
STK16 −2.447847745 0.167172273
KIAA1361 −2.423889248 0.278628419
PTK9L −2.410494224 0.188315746
SMG1 −2.399295519 0.410973636
HRI −2.356343115 0.164891125
PIK3CB −2.35237124 0.129565732
TEX14 −2.343029607 0.103570802
YES1 −2.321631399 0.077120421
Table W1. (continued )
Gene Name Average Fold Change of Hits SE
EPHB4 −2.31106718 0.03430319
MAP3K5 −2.309614642 0.213460796
PRKCH −2.305812348 0.110084865
CARKL −2.287657507 0.089229834
IHPK2 −2.282505672 0.102616739
MAP4K5 −2.273851307 0.210210796
MAP2K1 −2.267665047 0.109793074
LOC390877 −2.235943664 0.047785769
NEK3 −2.230754417 0.042361161
PSKH2 −2.195495073 0.057467012
MAP3K6 −2.172456025 0.153036382
RPS6KA2 −2.168817934 0.084144151
MAP3K14 −2.163783392 0.061843803
RIPK5 −2.145123976 0.054630149
TRIB2 −2.115623842 0.065188185
PCTK2 −2.096447377 0.018156421
CCRK 2.118202467 0.08253181
MAP2K6 2.149654232 0.142449621
NME4 2.166170508 0.155021545
PRKCE 2.305549835 0.155664995
CHKB 2.539373462 0.306909037
IKBKE 2.636668508 0.5907191
LOC91807 2.639602068 0.308744635
AKAP2 2.857215077 0.815885338
HIPK4 2.888470597 0.715055985
BUB1 2.928543253 0.494143058
ALK 2.98793913 0.773426548
FLJ22955 3.026932185 0.317449752
KIAA1811 3.05871072 0.983782766
ARAF1 3.08031827 0.634316473
IKBKG 3.203600237 0.55827589
ACK1 4.091616239 1.394816825
MAPKAPK5 4.757976644 0.08902561
